Respiratory Syncytial Virus Bronchiolitis in Children up to 5 Years of Age in Spain: Epidemiology and Comorbidities

Medicine (United States)

Volumn 94, Issue 21, 2015, Pages

  Gil Prieto, Ruth ^a   Gonzalez Escalada, Alba ^a,b   Marín García, Patricia ^a,c   Gallardo Pino, Carmen ^d   Gil De Miguel, Angel ^a  

^a UNIVERSIDAD REY JUAN CARLOS   (Spain)

^b Area of Medical Microbiology   (Spain)

^c Area of Medical Immunology   (Spain)

^d UAM)   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CAUSE OF DEATH; CHILD; COMORBIDITY ASSESSMENT; CONGENITAL HEART DISEASE; HOSPITALIZATION COST; HUMAN; HUMAN RESPIRATORY SYNCYTIAL VIRUS; INFANT; LENGTH OF STAY; LUNG DYSPLASIA; MAJOR CLINICAL STUDY; MORTALITY; NEWBORN; OBSERVATIONAL STUDY; PREMATURITY; PRESCHOOL CHILD; PRIORITY JOURNAL; RESPIRATORY SYNCYTIAL VIRUS INFECTION; RETROSPECTIVE STUDY; SEX DIFFERENCE; SPAIN; VIRAL BRONCHIOLITIS; BRONCHIOLITIS; COMORBIDITY; ECONOMICS; FEMALE; HOSPITALIZATION; INCIDENCE; MALE; MICROBIOLOGY; RESPIRATORY SYNCYTIAL VIRUS INFECTIONS; SEASON; STATISTICS AND NUMERICAL DATA;

BRONCHIOLITIS; CHILD, PRESCHOOL; COMORBIDITY; FEMALE; HOSPITALIZATION; HUMANS; INCIDENCE; INFANT; MALE; RESPIRATORY SYNCYTIAL VIRUS INFECTIONS; RETROSPECTIVE STUDIES; SEASONS; SPAIN;

EID: 84938899522     PISSN: 00257974     EISSN: 15365964     Source Type: Journal    
DOI: 10.1097/MD.0000000000000831     Document Type: Article

References (42)

1. Ochoa Sangrador C. Gonzalez de Dios J y Grupo de Revision del Proyecto aBREVIADo (BRonquiolitis-Estudio de Variabilidad, Ido-neidad y Adecuacion). Conferencia de Consenso sobre bronquiolitis aguda (II): epidemiología de la bronquiolitis aguda. Revision de la evidencia científica. An Pediatr (Barc). 2010;72:222e1-222e26.
2. Zhou H, Thompson WW, Viboud CG, et al. Hospitalizations associated with influenza and respiratory syncytial virus in the United States, 1993-2008. Clin Infect Dis. 2012;54:1427-1436.
3. Kristensen K, Hjuler T, Ravn H, et al. 1 chronic diseases, chromosomal abnormalities, and congenital malformations as risk factors for respiratory syncytial virus hospitalization: a population-based Cohort Study. Clin Infect Dis. 2012;54:810-817.
4. Nair H, Nokes DJ, Gessner BD, et al. Global burden of acute lower respiratory infections due to respiratory syncytial virus in young children: a systematic review and meta-analysis. Lancet. 2010;375:1545-1555.
5. Welliver RC. Respiratory syncytial virus and other respiratory viruses. Pediatr Infect Dis J. 2003;22:S6-12.
6. Blanken MO, Rovers MM, Molenaar JM, et al., Neonatal Network. Respiratory syncytial virus and recurrent wheeze in healthy preterm infants. N Engl J Med. 2013;368:1791-1799.
7. Falsey AR, Hennessey PA, Formica MA, et al., Walsh EEPh. Respiratory syncytial virus infection in elderly and high-risk adults. N Engl J Med. 2005;352:1749-1759.
8. Figueras Aloya J, López Sastre J, Medrano López C, et al. Consenso multidisciplinar español sobre la profilaxis de la infección respir-atoria pediátrica por virus respiratorio sincitial. An Pediatr (Barc). 2008;69:63-71.
9. Díez Domingo J, Ridao López M, Úbeda Sansano I, et al. Incidencia y costes de la hospitalización por bronquiolitis y de las infecciones por virus respiratorio sincitial en la Comunidad Valenciana. Años 2001 y 2002. An Pediatr (Barc). 2006;65:325-330.
10. Vicente D, Montes M, Cilla G, et al. Hospitalization for respiratory syncytial virus in the paediatric population in Spain. Epidemiol Infect. 2003;131:867-872.
11. Ministerio de Sanidad y Consumo. Clasificación internacional de enfermedades 9 revisión, modificación cĺinica. 1994.
12. Instituto Nacional de la Salud. Subdirección General de Coordina-ción Administrativa. Conjunto Mínimo Básico de Datos. Hospitales del INSALUD2001. Madrid 2002. http://www.ingesa.msc.es/.
13. Rivero Cuadrado A. El conjunto mínimo básico de datos en el SNS: inicios y desarrollo actual. Rev Fuentes Estadísticas 2000; 49:18-19. http://www.ingesa.msc.es/estadEstudios/documPublica/pdf/CMBD-2001.pdf. Accessed January 18. 2014.
14. Schreyögg J, Stargardt T, Tiemann O, et al. Methods to determine reimbursement rates for diagnosis related groups (DRG): a comparison of nine European countries. Health Care Manag Sci. 2006;9:215-223.
15. Gil-Prieto R, García-Garćia L, Alvaro-Meca A, et al. The burden of hospitalizations for meningococcal infection in Spain (1997-2008). Vaccine. 2011;29:5765-5770.
16. Gil Prieto R, San Román Montero J, Gómez Alejandre C, et al. Epidemiology of pneumococcal meningitis hospitalizations in pedia-tric population in Spain (1998-2006). Vaccine. 2009;27:2669-2673.
17. Montero JM, Prieto RG, Alejandre CG, et al. Hospital admissions for meningococcal infection in Spain (1997-2005). J Infect. 2009;58:15-20.
18. Gil-Prieto R, San Martín M, de Andrés AL, et al. Hospital-acquired rotavirus infections in Spain over a ten-year period (1998-2007). Hum Vaccin. 2009;5:748-753.
19. LG.Garćia-Garćia ML, Calvo C, Pozo F, et al. Spectrum of respiratory viruses in children with community-acquired pneumonia. Pediatr Infect Dis J. 2012;31:808-813.
20. Murray J1, Bottle A1, Sharland M2, et al., Medicines for Neonates Investigator Group. Risk factors for hospital admission with RSV bronchiolitis in England: a population-based birth cohort study. PLoS One. 2014;9:e89186doi: 10.1371/journal.pone.0089186. eCollection 2014.
21. Pezzotti P, Mantovani J, Benincori N, et al. Incidence and risk factors of hospitalization for bronchiolitis in preterm children: a retrospective longitudinal study in Italy. BMC Pediatr. 2009;9:56doi: 10.1186/1471-2431-9-56.
22. Carbonell-Estrany X, Figueras-Aloy J, Law BJ. Infección Respir-atoria Infantil por Virus Respiratorio Sincitial Study Group; Pediatric Investigators Collaborative Network on Infections in Canada Study Group. Identifying risk factors for severe respiratory syncytial virus among infants born after 33 through 35 completed weeks of gestation: different methodologies yield consistent findings. Pediatr Infect Dis J. 2004;23(11 Suppl):S193-S201.
23. Stockman LJ, Curns AT, Anderson LJ, et al. Respiratory syncytial virus-associated hospitalizations among infants and young children in the United States, 1997-2006. Pediatr Infect Dis J. 2012;31:5-9.
24. Liese JG, Grill E, Fischer B, et al., Munich RSV Study Group. Incidence and risk factors of respiratory syncytial virus-related hospitalizations in premature infants in Germany. Eur J Pediatr. 2003;162:230-236.
25. Gouyon JB, Rozé JC, Guillermet-Fromentin C, et al. Hospitalizations for respiratory syncytial virus bronchiolitis in preterm infants at <33 weeks gestation without bronchopulmonary dysplasia: the CASTOR study. Epidemiol Infect. 2013;141:816-826.
26. Falagas ME1, Mourtzoukou EG, Vardakas KZ. Sex differences in the incidence and severity of respiratory tract infections. Respir Med. 2007;101:1845-1863.
27. Simoes EA. Environmental and demographic risk factors for respiratory syncytial virus lower respiratory tract disease. J Pediatr. 2003;143:S118-S126.
28. Gupta R, Helms PJ, Jolliffe IT, et al. Seasonal variation in sudden infant death syndrome and bronchiolitis-a common mechanism? Am J Respir Crit Care Med. 1996;154 (2 Pt 1):431-435.
29. Moreno-Perez D, Calvo C. Five Study Group. Epidemiological and clinical data of hospitalizations associated with respiratory syncytial virus infection in children under 5 years of age in Spain: FIVE multicenter study. Influenza Other Respir Viruses. 2014;8:209-216.
30. Figueras-Aloy J, Carbonell-Estrany X, Quero-Jiménez J, et al. FLIP-2 Study: risk factors linked to respiratory syncytial virus infection requiring hospitalization in premature infants born in Spain at a gestational age of 32 to 35 weeks. Pediatr Infect Dis J. 2008;27:788-793.
31. Kristensen K, Hjuler T, Ravn H, et al. Chronic diseases, chromosomal abnormalities, and congenital malformations as risk factors for respiratory syncytial virus hospitalization: a population-based cohort study. Clin Infect Dis. 2012;54:810-817.
32. Sánchez-Solis M, Gartner S, Bosch-Gimenez V, et al. Is palivizumab effective as a prophylaxis of respiratory syncytial virus infections in cystic fibrosis patients? A meta-analysis. Allergol Immunopathol (Madr). 2013;43:298-303.
33. Rodriguez R, Ramilo O. Respiratory syncytial virus: how, why and what to do. J Infect. 2014;68 (suppl 1):S115-S118.
34. Hervás D, Reina J, Yañez A, et al. Epidemiology of hospitalization for acute bronchiolitis in children: differences between RSV and non-RSV bronchiolitis. Eur J Clin Microbiol Infect Dis. 2012;31:1975-1981.
35. Medrano López C, Garćia-Guereta L. CIVIC Study Group. Community-acquired respiratory infections in young children with congenital heart diseases in the palivizumab era: the Spanish 4-season civic epidemiologic study. Pediatr Infect Dis J. 2010;29:1077-1082.
36. Blanken MO, Rovers MM, Molenaar JM, et al., Dutch RSV Neonatal Network. Respiratory syncytial virus and recurrent wheeze in healthy preterm infants. N Engl J Med. 2013;368:1791-1799.
37. Nuijten MJ, Wittenberg W. Cost effectiveness of palivizumab in Spain: an analysis using observational data. Eur J Health Econ. 2010;11:105-115.
38. Resch B, Sommer C, Nuijten MJ, et al. Cost-effectiveness of palivizumab for respiratory syncytial virus infection in high-risk children, based on long-term epidemiologic data from Austria. Pediatr Infect Dis J. 2012;31:e1-e8.
39. Nuijten M, Lebmeier M, Wittenberg W. Cost effectiveness of palivizumab for RSV prevention in high-risk children in the Netherlands. Med Econ. 2009;12:291-300.
40. Garcia-Marcos L, Valverde-Molina J, Pavlovic-Nesic S, et al., the BCOST group. Pediatricians' attitudes and costs of bronchiolitis in the emergency department: a prospective multicentre study. Pediatr Pulmonol. 2014;49:1011-1019.
41. Shefali-Patel D, Paris MA, Watson F, et al. RSV hospitalization and healthcare utilisation in moderately prematurely born infants. Eur J Pediatr. 2012;171:1055-1061.
42. Peiro S, Librero J. Evaluación de la calidad a partir del conjunto mínimo de datos básicos al alta hospitalaria. Rev Neurol. 1999;29:651-661.